The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 1, 2006, Pages 3-8

  Koh, Stephen C L ^a   Khalil, R ^a   Lim, F K ^a   Ilancheran, A ^a   Choolani, M ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

ATIII; D dimer; Fibrinogen; Ovarian cancer; vWF

Indexed keywords

ANTITHROMBIN III; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEMOSTASIS; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; BIOLOGICAL MARKERS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; VON WILLEBRAND FACTOR;

EID: 32344445402     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960601200102     Document Type: Article

References (15)

1. Harlap S. The epidemiology of ovarian cancer. In: Markam M, Hoskins WJ, eds. Cancer of the Ovary. New York: Raven, 1993:79.
2. Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993-1997. Singapore Cancer Registry Report no. 5, 2000.
3. Bick RL. Coagulation abnormalities in malignancy: A review. Semin Thromb Haemost 1992;18:353.
4. Constantini V, Zacharski L-R. Fibrin and cancer. Thromb Haemost 1993;69:406.
5. Miyauchi S, Moroyama T, Kyoizumi S, et al. Malignant tumor cell lines produce interleukin-1 like factor. In Vitro Cell Dev Biol 1988;24:753.
6. Hajjar KA. Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995;74:294.
7. Koh SCL, Tham KF, Razvi K, et al. Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: Could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb/Hemost 2001;7:141.
8. Wersch van JWJ, Peters C, Ubachs JMH. Haemostasis in benign and malignant gynaecological tumours: A pilot study. Eur J Clin Chem Clin Biochem 1995;33:225.
9. von Tempelhof G-F, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian cancer. Thromb Haemost 1997;77:456.
10. Edwards CM, Warren J, Armstrong L, Donelly PK. D-dimer: A useful marker of disease in surgery for colorectal cancer. Br J Surg 1993;80:1404.
11. Beer JH, Haenerli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002; 88:745.
12. Ruggeri ZM, Ware J. The structure and formation of von Willebrand factor. Thromb Haemost 1992;67:594.
13. Ouden M Den, Ubachs JMH, Stoot JEGM, van Wersch JWJ. Thrombin- antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scand J Clin Lab Invest 1998;58:555.
14. Gaducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996; 60:197.
15. Gaducci A, Marrai P, Baicchi U, et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 1997;66:85.